Jado initiates phase II trails of lead RAFT modulator in urticaria
"The start of this systemic trial continues JADO's product development strategy in allergy. Having identified that miltefosine acts via a RAFT mechanism, we want to ensure that we continue to capture the value of the product in the allergy field with our formulations," noted Charl van Zyl, CEO of JADO. "We have made excellent progress with our studies and believe data from this study will continue to support our multi-faceted development program for TF002."
The randomized, double-blind, placebo-controlled study will enroll a total of 75 patients in 7 German centers. The primary end-point of the study is urticaria symptoms assessed by urticaria activity score (UAS) at the end of treatment.
JADO is investigating topical and oral versions of TF002 in Phase II trials in several allergy indications. Proof of concept with the topical formulation in a Phase II study of atopic dermatitis has been achieved. The company and academic collaborators also recently published in Science proof of concept for its Alzheimer's RAFT inhibitor program.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.